OR WAIT null SECS
January 11, 2022
Brief summary of EY’s 2022 M&A Firepower report highlights trends.
Ahead of the release of EY’s annual M&A Firepower report this week, Pharm Exec talks to EY’s Arda Ural to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.
January 04, 2022
Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.
December 09, 2021
Industry growth in innovation could spark financial rebound.
November 09, 2021
Regulatory headwinds are poised to ease as new year approaches.
October 12, 2021
Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.
While Q3 numbers look bleak, is improvement on the horizon?
September 14, 2021
Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.
When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.
August 27, 2021
With large M&A deals comes a complex Market Authorization Transfer (MAT) process, during which regulatory teams must weigh several operational aspects while creating a roadmap that takes them into account. Cecile Riboud outlines some key questions that are necessary for planning and executing a successful MAT process.
